Clinical Trials Browser

Phase NA × HER2-positive Breast Cancer × pertuzumab × Clear all

NCT07115095 2025-08-11

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Phase NA Completed

HER2-positive Breast Cancer